Skip to Main Content

Paper Details

Targeting the mevalonate pathway suppresses ARID1A-inactivated cancers by promoting pyroptosis.
Cancer Cell
11
2023
-inactivated cells, ARID1A, ARID1A mutant, ARID1A-, ARID1A-inactivated cancers, ARID1A-inactivated cells, Arid1a, HMGCR, HMGCS1, ICB, OCCC, OCCCs, PD-L1 antibody, SNF, SNF complex, SWI, anti-, cancers, clear cell ovarian carcinoma, humanized, humanized immunocompetent ARID1A mutant, mevalonate, mouse, mutated, patient, simvastatin, tumor, wild-type, OCCCs
Author NameAffiliation
Andrew V KossenkovThe Wistar Institute
Ronny DrapkinPerelman School of Medicine, University of Pennsylvania, Penn Ovarian Cancer Research Center
Ronny DrapkinPerelman School of Medicine, University of Pennsylvania, Penn Ovarian Cancer Research Center
Luis J MontanerThe Wistar Institute
  • 1 - 4

Datasets

Release 1.2